Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Valsartan combined with sacubitril (neprilysin inhibitor) improves heart failure patient survival. |
 |
 |
| CBS: Entresto users had a 21.8 percent rate of deaths or hospitalization within 27 months, while enalapril users had a 26.5 percent rate. Entresto is different from ACE inhibitors because it's a dual-component drug that combines the company's blood pressure drug, Diovan (valsartan), with the drug sacubitril, which inhibits an enzyme present in heart failure, called neprilysin. |
